If you have held Replimune shares continuously since prior to November 22, 2024, you may have standing to seek corporate governance reforms at Replimune, including improvements to internal controls, transparency, and executive oversight.

or contact Johnson Fistel, PLLP at jimb@johnsonfistel.com or (619) 814-4471.

Complaint Allegations
The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) defendants recklessly overstated the IGNYTE trial’s prospects, given material issues that defendants knew or should have known of, which resulted in the FDA deeming the IGNYTE trial inadequate and not well-controlled; and (2) as a result, defendants’ statements about Replimune’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.